Novavax vs Repligen
Novavax reported revenue of $1.1 billion in fiscal 2025, 1.5 times Repligen's $738 million in fiscal 2025. Novavax's revenue grew 64.7% in its latest year, and Repligen's grew 16.4%. Novavax had an operating margin of 40.3%, against 7.5% at Repligen. Free cash flow was −$250 million at Novavax and $94 million at Repligen.
Side by side
| Novavax | Repligen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.1B | $738M |
| Revenue growth | 64.7% | 16.4% |
| Revenue growth a year, last 5 years | 18.8% | 15.0% |
| Gross margin | 93.5% | 52.3% |
| Operating margin | 40.3% | 7.5% |
| Net margin | 39.2% | 6.6% |
| Free cash flow | −$250M | $94M |
| Free cash flow margin | −22.3% | 12.7% |
| Return on capital | — | 2.4% |
| Net debt to EBITDA | −1.0x | −1.7x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 13.7% | — |
| Last close | $10.78 | $173.49 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $14.2 million |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
NovavaxRepligen
Operating margin
Percent of revenue
NovavaxRepligen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NovavaxRepligen